Experimental protein for severe stable angina
Part of Heart & circulation clinical trials.
This study tests an experimental protein called FGF-1 that is injected directly into the heart to help grow new small blood vessels, potentially improving blood flow and reducing chest pain. It is for people with severe, stable angina who cannot have standard revascularization procedures like stents or bypass surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 25 and 75 years old.
- You have had stable chest pain (angina) for at least 3 months that is not well controlled with current medications.
- Your angina is severe enough to limit normal daily activities (class III or IV), and your doctor has said that angioplasty or bypass surgery is not an option for you.
- Your heart's pumping function (ejection fraction) is at least 30%.
- You do not have severe retinopathy (eye disease) or active cancer.
- You are able to walk on a treadmill for about 3 to 9 minutes during a stress test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy (XC001) delivered through a thin tube into your heart's blood vessels. It aims to grow new blood vessels to relieve chest pain in people with chronic angina who have no other treatment options.
This trial studies how heart disease affects the heart using heart imaging, and looks at people with chest pain/angina or heart failure with preserved pumping strength (HFpEF). It may help doctors better understand what’s driving symptoms and how best to evaluate these conditions.
This Phase 2 trial tests whether stem cells placed into the heart artery can safely reduce symptoms in people with “refractory” angina (chest pain) despite maximum heart-healthy medication. You may qualify if your chest pain is limiting your activity and other heart procedures (stents/bypass) aren’t possible or are too risky.
This trial tests whether implanting a small device in the heart’s coronary sinus can reduce symptoms in people with long-lasting “refractory” angina despite taking the usual heart medicines. It may help improve how much activity you can do and reduce angina-related limitations.
This study follows people who have narrowed heart arteries and have a pressure test (FFR) to guide treatment. It may help doctors understand the course of disease when using FFR and choosing a minimally invasive approach.
This trial tests a small device called a coronary sinus reducer that is placed in a vein of the heart to improve blood flow and reduce chest pain in people who still have angina despite medications and cannot have stents or bypass surgery. The procedure is done through a small tube in the groin or arm.
Hear when a new Coronary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.